Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc has reduced its stake in Krystal Biotech, Inc. by 34.6%, now owning approximately 0.13% of the company worth $6.7 million.
• Other institutional investors have increased their holdings, with Fifth Third Bancorp boosting shares by 159.1% in the same quarter.
• Krystal Biotech reported an earnings per share of $1.29, surpassing expectations, and has seen various analysts adjust their price targets, with a consensus target of $210.75.

Aberdeen Group plc lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,301 shares of the company's stock after selling 19,732 shares during the quarter. Aberdeen Group plc owned approximately 0.13% of Krystal Biotech worth $6,725,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. raised its holdings in Krystal Biotech by 8.9% during the first quarter. Fox Run Management L.L.C. now owns 2,354 shares of the company's stock worth $424,000 after purchasing an additional 193 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in Krystal Biotech by 16.8% during the first quarter. E Fund Management Co. Ltd. now owns 2,258 shares of the company's stock worth $407,000 after purchasing an additional 324 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Krystal Biotech by 8,390.1% during the first quarter. Russell Investments Group Ltd. now owns 37,781 shares of the company's stock worth $6,812,000 after purchasing an additional 37,336 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in Krystal Biotech by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 80,264 shares of the company's stock worth $14,472,000 after purchasing an additional 17,254 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Krystal Biotech during the first quarter worth approximately $42,223,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. The trade was a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Stock Up 3.3%

NASDAQ:KRYS traded up $4.79 during midday trading on Friday, reaching $150.49. The stock had a trading volume of 246,954 shares, compared to its average volume of 428,473. The firm has a fifty day simple moving average of $144.22 and a two-hundred day simple moving average of $154.55. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The stock has a market cap of $4.36 billion, a P/E ratio of 30.59 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on KRYS shares. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America cut their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Chardan Capital cut their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Friday. Finally, Citigroup reaffirmed a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $210.38.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).